Logo of nihpaLink to Publisher's site
PMC full text:
Cancer Immunol Res. Author manuscript; available in PMC 2017 Nov 1.
Published in final edited form as:
Cancer Immunol Res. 2016 Nov; 4(11): 910–916.
Published online 2016 Oct 13. doi: 10.1158/2326-6066.CIR-16-0201
Copyright/LicenseRequest permission to reuse

Figure 2

An external file that holds a picture, illustration, etc. Object name is nihms827180f2.jpg
PFS by β2M, MHC class I, and MHC class II expression in the cHL cohort

(A) PFS for patients with positive (Pos), decreased (Dec) and negative (Neg) HRS cell membrane expression of β2M (left panel), MHC class I (middle panel) and MHC class II (right panel). (B) PFS for patients with positive vs. decreased/negative HRS cell expression of β2M (left panel), MHC class I (middle panel) and MHC class II (right panel). (C) PFS for patients whose HRS cells have positive or decreased/negative β2M (left panel), MHC class I (middle panel) and MHC class II (right panel) expression in the presence or absence of PD-L1/PD-L2 amplification.

Images in this article

  • Figure 1
  • Figure 2

Click on the image to see a larger version.

-